[1]邓婕,段东.甲状腺微小乳头状癌的治疗进展[J].国际放射医学核医学杂志,2018,(5):463-467.[doi:10.3760/cma.j.issn.1673-4114.2018.05.014]
　Dengjie,Duandong.Progress in the treatment of papillary thyroid microcarcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):463-467.[doi:10.3760/cma.j.issn.1673-4114.2018.05.014]
点击复制

甲状腺微小乳头状癌的治疗进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第5期
页码:
463-467
栏目:
综述
出版日期:
2018-10-01

文章信息/Info

Title:
Progress in the treatment of papillary thyroid microcarcinoma
作者:
邓婕;  段东
400016, 重庆医科大学附属第一医院核医学科
Author(s):
Dengjie;  Duandong
Department of Nuclear Medicine, Chongqing Medical University, Chongqing 400016, China
关键词:
甲状腺肿瘤; 治疗; 随访; 激素抑制
Keywords:
Thyroid neoplasms;  Therapy;  Follow-up;  Hormone suppression
DOI:
10.3760/cma.j.issn.1673-4114.2018.05.014
摘要:
甲状腺癌，特别是甲状腺微小乳头状癌（PTMC）总体预后良好，因此以往临床医师没有足够重视。近年来，随着PTMC的发病率越来越高，学者对其研究更加深入，国际指南和国内专家均对其越来越重视，对其诊治做了相应推荐。由于缺乏大量的循证医学证据，目前国内外对PTMC的诊治还存在许多争议，笔者对PTMC治疗中争议较大的问题进行综述。
Abstract:
In the past, clinicians paid little attention to thyroid cancers, particularly papillary thyroid microcarcinoma (PTMC), given their good overall prognoses. Recently, however, international and domestic researchers have given increased attention to PTMC and its diagnosis and treatment because of the increasing incidence of this malignancy. The diagnosis and treatment of PTMC remain controversial at home and abroad given their lack of evidence-based medical evidence. This paper summarizes the controversies surrounding the treatment of PTMC.

参考文献/References:

[1] Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors:a commentary on the second edition[J]. Cancer, 1989, 63 (5):908-911.
[2] 林岩松, 杨雪. 甲状腺微小癌-131I治疗[J]. 中国实用外科杂志, 2016, 36 (5):527-530. DOI:10.7504/CJPS.ISSN 1005-2208. 2016.05.16. Lin YS, Yang X. Radioactive iodine-131 therapy of papillary thyroid microcarcinoma[J]. Chin J Pract Surg, 2016, 36 (5):527-530.
[3] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26 (1):1-133. DOI:10.1089/thy.2015.0020.
[4] Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients[J]. World J Surg, 2010, 34 (1):28-35. DOI:10.1007/s00268-009-0303-0.
[5] Haser GC, Tuttle RM, Su HK, et al. Active surveillance for papillary thyroid microcarcinoma:new challenges and opportunities for the health care system[J]. Endocr Pract, 2016, 22 (5):602-611. DOI:10.4158/EP151065.RA.
[6] 张浩. 甲状腺微小乳头状癌外科治疗争议与共识[J]. 中国实用外科杂志, 2016, 36 (5):504-508. DOI:10.7504/CJPS.ISSN1005-2208.2016.05.09. Zhang H. Consensus and controversy on surgical treatment of papillary thyroid microcarcinoma[J]. Chin J Pract Surg, 2016, 36 (5):504-508.
[7] 中国抗癌协会甲状腺癌专业委员会. 甲状腺微小乳头状癌诊断与治疗中国专家共识 (2016版)[J]. 中国肿瘤临床, 2016, 43 (10):405-411. DOI:10.3969/j.issn.1000-8179.2016.10.001. China anti-cancer association’s specialist committee on thyroid carcinoma. Diagnosis and treatment of papillary thyroid microcarcinoma in China (2016 edition)[J]. Chin J Clin Oncol, 2016, 43 (10):405-411.
[8] Wang TS, Goffredo P, Sosa JA, et al. Papillary thyroid microcarcinoma:an over-treated malignancy?[J]. World J Surg, 2014, 38 (9):2297-2303. DOI:10.1007/s00268-014-2602-3.
[9] 张伟伟, 李向农. 三种术式在甲状腺微小乳头状癌外科治疗中的应用效果比较[J]. 中华普外科手术学杂志 (电子版), 2017,11 (5):397-399. DOI:10.3877/cma.j.issn.1674-3946.2017.05.014. Zhang WW, Li XN. Three operative procedures in the surgical treatment of papillary thyroid microcarcinoma[J]. Chin J Oper Proc Gen Surg (Electronic Edition), 2017, 11 (5):397-399.
[10] Donatini G, Castagnet M, Desurmont T, et al. Partial Thyroidectomy for Papillary Thyroid Microcarcinoma:Is Completion Total Thyroidectomy Indicated?[J]. World J Surg, 2016, 40 (3):510-515. DOI:10.1007/s00268-015-3327-7.
[11] 朱精强, 雷建勇. 甲状腺微小乳头状癌过度治疗与不足[J]. 中国实用外科杂志, 2016, 36 (5):520-523. DOI:10.7504/CJPS.ISSN 1005-2208.2016.05.14. Zhu JQ, Lei JY. Over-treatment and under-treatment of papillary thyroid microcarcinoma[J]. Chin J Pract Surg, 2016, 36 (5):520-523.
[12] Kuo EJ, Goffredo P, Sosa JA, et al. Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases:a population-level analysis[J]. Thyroid, 2013, 23 (10):1305-1311. DOI:10.1089/thy.2012.0563.
[13] Li F, Chen G, Sheng C, et al. BRAFV600E mutation in papillary thyroid microcarcinoma:a meta-analysis[J]. Endocr Relat Cancer, 2015, 22 (2):159-168. DOI:10.1530/ERC-14-0531.
[14] Caliskan M, Park JH, Jeong JS, et al. Role of prophylactic ipsilateral central compartment lymph node dissection in papillary thyroid microcarcinoma[J]. Endocr J, 2012, 59 (4):305-311. DOI:10.1507/endocrj.EJ11-0366.
[15] So YK, Son YI, Hong SD, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma:a study of 551 resections[J]. Surgery, 2010, 148 (3):526-531. DOI:10.1016/j.surg.2010.01.003.
[16] 卞雪艳, 孙姗姗, 郭文宇, 等. 甲状腺微小乳头状癌颈淋巴结转移的危险因素分析[J]. 中国肿瘤临床, 2015, 42 (13):658-662. DOI:10.3969/j.issn.1000-8179.20150156. Bian XY, Sun SS, Guo WY, et al. Risk factor analysis for cervical nodal metastasis in papillary microcarcinoma[J]. Chin J Clin Oncol,2015, 42 (13):658-662.
[17] 边学海, 李世杰, 张广, 等. 甲状腺微小乳头状癌颈淋巴结转移影响因素的初步研究 (附1180例报道)[J]. 国际外科学杂志, 2013, 40 (2):105-108. DOI:10.3760/cma.j.issn.1673-4203. 2013. 02.010. Bian XH, Li SJ, Zhang G, et al. Effective factors of cervical lymph node metastasis of papillary thyroid microcarcinoma (1180 cases)[J].Inter J Surg, 2013, 40 (2):105-108.
[18] 刘晓岭, 黄靖, 孙德胜, 等. 超声引导下射频消融治疗甲状腺微小乳头状癌的临床体会[J]. 黑龙江医学, 2015, 39 (1):69-70. DOI:10.3969/j.issn.1004-5775.2015.01.035. Liu XL, Huang J, Sun DS, et al. Experience of Radiofrequency Ablation Treatment of Thyroid Papillary Microcarcinoma Under Ultrasound Guidance[J]. Heilongjiang Med J, 2015, 39 (1):69-70.
[19] Zhang M, Luo Y, Zhang Y, et al. Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation for Treating Low-Risk Papillary Thyroid Microcarcinoma:A Prospective Study[J]. Thyroid, 2016, 26 (11):1581-1587. DOI:10.1089/thy.2015.0471.
[20] 李建如, 罗渝昆, 李岩密, 等. 超声引导下射频消融治疗甲状腺微小乳头状癌的疗效分析[J]. 解放军医学院学报, 2016, 37 (8):823-826. DOI:10.3969/j.issn.2095-5227.2016.08.002. Li JR, Luo YK, Li YM, et al. Effects of radiofrequency ablation guided by ultrasound in treatment of thyroid papillary tiny carcinoma[J]. Acad J Chin PLA Med Sch, 2016, 37 (8):823-826.
[21] 张浩, 孙威. 射频消融治疗甲状腺微小乳头状癌之我见[J]. 医学与哲学, 2017, 38 (7B):19-21, 51. DOI:10.12014/j.issn.1002-0772. 2017.07b.05. Zhang H, Sun W. Personal Insight into Radiofrequency Ablation for the Treatment of papillary Thyroid Microcarcinoma[J]. Med Philos, 2017, 38 (7B):19-21, 51.
[22] 王平, 燕海潮. 完全腔镜甲状腺癌手术并发症的防治[J]. 腹腔镜外科杂志, 2012, 17 (11):806-809. DOI:10.3969/j.issn.1009-6612. 2012.11.003 Wang P, Yan HC. Prevention and treatment of complications of complete endoscopic thyroid carcinoma[J]. J Laparoscopic Surg, 2012, 17 (11):806-809.
[23] 陈峰, 张保根. 90例经胸乳入路腔镜下甲状腺手术[J]. 中华内分泌外科杂志, 2013, 7 (1):16-18. DOI:10.3760/cma.j.issn.1674-6090.2013.01.006. Chen F, Zhang BG. Endoscopic thyroidectomy via the breast areolae:90 cases[J]. Chin J Endocr Surg, 2013, 7 (1):16-18.
[24] Mihailovic J, Stefanovic L, Stankovic R. Influence of initial treatment on the survival and recurrence in patients with differentiated thyroid microcarcinoma[J]. Clin Nucl Med, 2013, 38 (5):332-338. DOI:10.1097/RLU.0b013e3182872ed2.
[25] 李志红. 促甲状腺激素抑制疗法在分化型甲状腺癌治疗中的作用[J]. 实用临床医药杂志, 2013, 17 (9):107-108. DOI:10.7619/jcmp.201309039. Li ZH. Value of thyroid stimulating hormone inhibition therapy in differentiated thyroid carcinoma[J]. J Clin Med Pract, 2013, 17 (9):107-108.
[26] 关海霞. 甲状腺微小癌术后促甲状腺激素抑制治疗认识和挑战[J]. 中国实用外科杂志, 2016, 36 (5):524-527. DOI:10.7504/CJPS. ISSN 1005-2208.2016.05.15. Guan HX. Thyrotropin suppression therapy in thyroid microcarcinoma:Current understanding and challenges[J]. Chin J Prat Surg, 2016, 36 (5):524-527.

相似文献/References:

[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
　Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
　Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
　Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[5]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
　Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[6]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[7]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
　Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[8]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
　Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[9]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
　Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[10]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
　Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
[11]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
　Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]

备注/Memo

备注/Memo:
收稿日期:2018-03-19。
通讯作者:段东,Email:duandong26@163.com
更新日期/Last Update: 2018-10-01